Provided by Tiger Trade Technology Pte. Ltd.

SIMCERE PHARMA

12.130
0.000
Volume:5.75M
Turnover:69.46M
Market Cap:31.49B
PE:37.25
High:12.270
Open:12.270
Low:11.960
Close:12.130
52wk High:15.080
52wk Low:6.099
Shares:2.60B
HK Float Shares:2.60B
Volume Ratio:1.12
T/O Rate:0.22%
Dividend:0.17
Dividend Rate:1.44%
EPS(LYR):0.326
ROE:12.45%
ROA:6.50%
PB:3.90
PE(LYR):37.25
PS:3.97

Loading ...

Guojin Securities Initiates Coverage on Simcere Pharma (02096) with "Buy" Rating, Targets HK$20.16

Stock News
·
Dec 29, 2025

Securing a $7.4 Billion Mega-Deal, $17 Billion Pharma Tycoon Ren Jinsheng is on a Winning Streak

Deep News
·
Dec 25, 2025

Simcere Pharma Gets China Nod for Tumor Drug Trial

MT Newswires Live
·
Dec 23, 2025

SIMCERE PHARMA (02096): SIM0610 (EGFR/cMET Bispecific Antibody-Drug Conjugate) Receives Clinical Trial Approval from NMPA

Stock News
·
Dec 23, 2025

Simcere Pharmaceutical - Sim0610 Receives Clinical Trial Approval From Nmpa China

THOMSON REUTERS
·
Dec 23, 2025

Simcere Pharmaceutical Group Receives China Approval to Begin Clinical Trials for SIM0610 Bispecific Antibody-Drug Conjugate

Reuters
·
Dec 23, 2025

Hong Kong Stock Announcement Highlights | Sanhua Intelligent Controls Issues Profit Alert with Expected Annual Net Profit Growth of 25%-50%

Stock News
·
Dec 22, 2025

SIMCERE PHARMA (02096) Subsidiary Enters Exclusive Licensing Agreement with Ipsen for SIM0613 (LRRC15-Targeting ADC)

Stock News
·
Dec 22, 2025

Simcere Pharmaceutical - Ipsen to Have Exclusive Global Rights for Sim0613

THOMSON REUTERS
·
Dec 22, 2025

Simcere Pharmaceutical - Unit Enters Licensing Agreement With Ipsen Pharma Sas

THOMSON REUTERS
·
Dec 22, 2025

Simcere Pharmaceutical -Under Group, Group Eligible to Receive up to US$1,060 Mln

THOMSON REUTERS
·
Dec 22, 2025

Simcere Pharmaceutical Signs Exclusive Licensing Agreement With Ipsen for SIM0613

Reuters
·
Dec 22, 2025

Simcere Pharmaceutical Group (SEHK:2096): Valuation Check After ENZESHU Insurance Inclusion and ENDOSTAR NRDL Renewal

Simply Wall St.
·
Dec 21, 2025

Hong Kong Stocks Movement | VIGONVITA-B (02630) Surges Over 15% in Afternoon Trading After Licensing Agreement with SIMCERE PHARMA for VV116 New Indications

Stock News
·
Dec 17, 2025

Guojin Securities Initiates Coverage on SIMCERE PHARMA (02096) with "Buy" Rating, Targets HK$20.16

Stock News
·
Dec 15, 2025

China Adds Simcere's Enzeshu to National Reimbursement List, Endostar Secures Renewal

MT Newswires Live
·
Dec 08, 2025

SIMCERE PHARMA (02096): Enzastaurin® and Endostar® Included in China's Updated National Reimbursement Drug List

Stock News
·
Dec 08, 2025

BOCOM INTL: China's 1st-8th Batch National Drug Procurement Renewal Rules Likely Moderate, Short-Term Catalysts Ample

Stock News
·
Dec 05, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

Simcere (2096) Enters Exclusive Licensing with Vigonvita (2630.HK) for Deuterated Remdesivir Hydrobromide

Bulletin Express
·
Dec 03, 2025